Effectiveness of a Physical Therapy Telerehabilitation Program in Long Post COVID-19 Symptoms in Primary Health Care.

Not Applicable

Completed

• Conditions: COVID-19; Physical Therapy Modalities; Telerehabilitation; Primary Health Care

• Registration Number: NCT05121688
• Lead Sponsor: Universidad Complutense de Madrid

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-11-10
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Inclusion Criteria:<br><br> - Patients with long post-COVID symptoms (from week 12 to week 24).<br><br> - Patients between 25 and 70 years old.<br><br> - Patients with moderate respiratory and/or functional affectation with long post<br> COVID-19 symptoms, belonging to four Physiotherapy Units of primary Health Care in<br> Madrid (Spain).<br><br> - Confirmed diagnosis of COVID-19 via a positive nasopharyngeal or throat swab within<br> the past 12 months.<br><br> - Persistent symptoms lasting =12 weeks since the first positive test, including<br> dyspnea (new or increased from baseline as measured by modified Medical Research<br> Council (mMRC) score =1).<br><br> - Normal oxygen saturation (greater than 90%) by pulse oximetry at rest on room air.<br><br> - Participant owns a smart phone, tablet, or computer to access on-line sessions.<br><br>Exclusion Criteria:<br><br> - People with symptoms such as fever, cough, upper respiratory distress, diarrhea,<br> vomiting, anosmia or ageusia.<br><br> - Temperature greater than 37.2 degrees Celsius.<br><br> - Patients with multimorbidity. Multimorbidity will be considered when the patient is<br> diagnosed with two or more diseases among the following: diabetes, dyslipidaemia,<br> cardiovascular disease (arterial hypertension, ischemic heart disease, valvular<br> heart disease, heart failure), osteoarthritis, respiratory disease (asthma, chronic<br> bronchitis), digestive disease ( gastric or duodenal ulcers, inflammatory bowel<br> disease, liver disease), psychiatric pathology or tumor pathology.<br><br> - Patients with previous pathologies: ischemic heart disease, dementia, lung failure,<br> lung cancer, cystic fibrosis, pulmonary fibrosis, chronic kidney failure, liver<br> diseases, myocardial arrhythmias, deep vein thrombosis, severe aortic stenosis,<br> liver diseases.<br><br> - Patients with weakened immune systems: in cancer treatment, organ or marrow<br> transplant patients, HIV/AIDS, prolonged use of prednisone or similar medication.<br><br> - Patients with functional limitations to carry out their basic activities of daily<br> living. Barthel index greater than 90.<br><br> - Patients with cognitive problems. Mini-Cognitive Lobo exam greater than 23 points<br><br> - Active bleeding.<br><br> - Unstable fractures.

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Modified Borg scale.;Modified Borg scale.;Modified Borg scale.;Modified Borg scale.

Secondary Outcome Measures

Name	Time	Method
Modified Medical Research Council Dyspnea Score.;Modified Medical Research Council Dyspnea Score.;Modified Medical Research Council Dyspnea Score.;Modified Medical Research Council Dyspnea Score.;Saint George Respiratory Questionnaire.;Saint George Respiratory Questionnaire.;Saint George Respiratory Questionnaire.;Saint George Respiratory Questionnaire.;6-Minute Walk Test (6MWT).;6-Minute Walk Test (6MWT).;6-Minute Walk Test (6MWT).;6-Minute Walk Test (6MWT).